poisar

Stocks · News reference

Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

Jul 28, 2026, 11:42 AMBenzinga Newsdesk

Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight to Equal-Weight and lowers the price target from $34 to $21.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MPLT
Source
benzinga
Observed
Jul 28, 2026, 11:42 AM
Checked
Jul 28, 2026, 11:42 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 13, 2026, 8:51 PMSEC EDGAR

    8-K filing — MapLight Therapeutics, Inc. (MPLT)

    Filed: 2026-08-13 AccNo: 0001193125-26-349490 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    Read original at edgar
    MPLT